Arthur F. Ryan - 09 Feb 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/ Arthur F. Ryan
Issuer symbol
REGN
Transactions as of
09 Feb 2026
Net transactions value
-$77,853
Form type
4
Filing time
11 Feb 2026, 16:02:23 UTC
Previous filing
06 Jan 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RYAN ARTHUR F Director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN /s/ Arthur F. Ryan 11 Feb 2026 0001187443

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $776 -1 -0.01% $775.63 17,902 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $7,766 -10 -0.06% $776.59 17,892 09 Feb 2026 Direct F1, F2
transaction REGN Common Stock Sale $44,321 -57 -0.32% $777.56 17,835 09 Feb 2026 Direct F1, F3
transaction REGN Common Stock Sale $9,342 -12 -0.07% $778.53 17,823 09 Feb 2026 Direct F1, F4
transaction REGN Common Stock Sale $3,897 -5 -0.03% $779.41 17,818 09 Feb 2026 Direct F1, F5
transaction REGN Common Stock Sale $780 -1 -0.01% $780.09 17,817 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $3,907 -5 -0.03% $781.48 17,812 09 Feb 2026 Direct F1, F6
transaction REGN Common Stock Sale $783 -1 -0.01% $782.53 17,811 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $2,350 -3 -0.02% $783.34 17,808 09 Feb 2026 Direct F1, F7
transaction REGN Common Stock Sale $785 -1 -0.01% $784.59 17,807 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $786 -1 -0.01% $785.71 17,806 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $1,573 -2 -0.01% $786.29 17,804 09 Feb 2026 Direct F1
transaction REGN Common Stock Sale $788 -1 -0.01% $787.82 17,803 09 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2 Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F3 Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F4 Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F5 Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F6 Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F7 Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.